Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine crawled time : 05:00 save search
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Published: 2023-09-07 (Crawled : 05:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.55%
candidate disease report vaccine positive valneva results phase 2
Cancer Vaccines Push Toward Viability with New Approaches and Targets
Published: 2022-09-23 (Crawled : 05:00) - biospace.com/
IMV | $0.8225 -2.74% 45K
|
Health Technology
| Email alert
Add to watchlist
cancer vaccine
Clinical Catch-Up: 3's the Charm for Pfizer-BioNTech Vaccine in Kids & More
Published: 2022-05-30 (Crawled : 05:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
vaccine
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
Published: 2021-12-16 (Crawled : 05:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.18%
H: 0.0%
C: 0.0%
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 5.55%
H: 0.0%
C: 0.0%
covid-19 new drug application drug approval covid vaccine submission
GHIT Fund Announces New Investments: A Total of 750 Million Yen in Drugs for Malaria and Chagas Disease, Vaccine for Malaria, and Diagnostics for Tuberculosis
Published: 2021-11-04 (Crawled : 05:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.35%
H: 0.91%
C: 0.77%
disease vaccine drug diagnostics diagnostic malaria
Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001
Published: 2021-09-23 (Crawled : 05:00) - globenewswire.com
DVAX | $11.78 3.88% 3.74% 9.3M
|
Health Technology
|
| O: -4.58%
H: 9.31%
C: 9.31%
covid clinical trials expansion vaccine trials vla2001 trial covid-19
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
Published: 2021-09-14 (Crawled : 05:00) - globenewswire.com
DVAX | $11.78 3.88% 3.74% 9.3M
|
Health Technology
|
| O: -1.15%
H: 1.03%
C: -4.46%
covid vaccine phase 3 trial covid-19
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
Published: 2021-07-19 (Crawled : 05:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.17%
H: 0.7%
C: 0.2%
disease phase 2 vaccine trial
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
Published: 2021-06-09 (Crawled : 05:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.39%
H: 2.15%
C: 2.08%
fda vaccine fda approval order pneumococcal
Teekay Welcomes US-Based Seafarer COVID-19 Vaccination Access
Published: 2021-05-26 (Crawled : 05:00) - teekay.com
TNK | $56.53 1.82% 0.0% 330K
|
Transportation
|
| O: -0.2%
H: 2.59%
C: 1.0%
TK | $7.26 2.83% 0.0% 500K
|
Transportation
|
| O: -1.16%
H: 4.39%
C: 3.51%
covid vaccine covid-19
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
Published: 2020-12-12 (Crawled : 05:00) - globenewswire.com
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
covid vaccine authorized covid-19
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
DBRG | $17.3 0.06% 1.97% 1.2M
|
Finance and Insurance
OSK 4 | $117.72 0.05% 1.96% 370K
|
Producer Manufacturing
HYLN 4 | $1.29 -2.27% 1.55% 680K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.